IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

Represents an inventory impairment charge of $1.3 million related to the January 2026 voluntary recall of select lots of bioidentical hormone pellets shipped by Asteria Health between May 2025 and ...

Management rebuilt the commercial organization in 2025, grew the salesforce to just over 90 and plans to expand to approximately 120 in 2026 while investing in technology—moves management says are ...

COLUMBUS, GA, UNITED STATES, March 3, 2026 /EINPresswire.com/ — OBGYN Specialists of Columbus is helping women better understand Bioidentical Hormone Replacement ...

Image source: The Motley Fool. biote (NASDAQ:BTMD) reported lower total and procedure revenues, attributed to elevated clinic attrition and a voluntary product recall, but offset these pressures with ...

biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...

We recently published a list of 10 Micro-Cap Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where biote Corp. (NASDAQ:BTMD) stands against other micro-cap ...

These may include BioTE bioidentical hormone pellets, transdermal formulations, or injections. For patients choosing BioTE, an in-office pellet insertion is scheduled with clear expectations regarding ...